Skip to main navigation Skip to search Skip to main content

Multifaceted Role of the Transforming Growth Factor β on Effector T Cells and the Implication for CAR-T Cell Therapy

  • Apolline de Folmont
  • , Jean Henri Bourhis
  • , Salem Chouaib
  • , Stéphane Terry
  • Institut national de la santé et de la recherche médicale
  • Unité INSERM U753, Institut de Cancérologie Gustave Roussy

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Evading the immune system is one of the hallmarks of cancer. Tumors escape anti-tumor immunity through cell-intrinsic means and the assembly of an immunosuppressive tumor microenvironment. By significantly boosting the host immune system, cancer immunotherapies targeting immune checkpoint receptors (CTLA-4 and PD-1) improved survival in patients even with cancers previously considered rapidly fatal. Nevertheless, an important group of patients is refractory or relapse rapidly. The factors involved in the heterogeneous responses observed are still poorly understood. Other immunotherapeutic approaches are being developed that may widen the options, including adoptive cell therapy using CAR-T cells alone or in combination. Despite impressive results in B cell malignancies, many caveats and unanswered questions remain in other cancers, thus limiting the potential of this approach to treat aggressive diseases. In particular, a complex TME could impair the survival, proliferation, and effector functions of CAR-T cells. Recent reports highlight the potential of targeting TGF-β signaling to improve CAR-T cell therapy. TGF-β is a well-known regulatory cytokine with pleiotropic effects in the TME, including immunosuppression. This review summarizes recent work investigating the potential effects of TGF-β within the TME, with a focus on CAR-T behavior and efficacy. We also discuss several key questions to be addressed to accelerate clinical translation of this approach.

Original languageEnglish
Pages (from-to)160-173
Number of pages14
JournalImmuno
Volume1
Issue number3
DOIs
StatePublished - Sep 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CAR-T
  • TGF-beta
  • adoptive T-cell therapy
  • immunotherapy
  • lymphocyte
  • tumor microenvironment

Fingerprint

Dive into the research topics of 'Multifaceted Role of the Transforming Growth Factor β on Effector T Cells and the Implication for CAR-T Cell Therapy'. Together they form a unique fingerprint.

Cite this